Immune Globulin Intravenous Injection |
Gamimune N; Gammagard S/D; Gammar-IV; Gammar-P I.V.; IGIV; Iveegam; Panglobulin; Polygam S/D; Sandoglobulin; Venoglobulin-S |
Clinical Trial: Cocaine-Metyrapone Interaction Study - 1
This study is no longer recruiting patients.
Purpose
The purpose of this study is to examine the safety of two consecutive days of metyrapone (MRP) in subjects who may use cocaine concurrently.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cocaine-Related Disorders Infusions, Intravenous | Drug: Metyrapone | Phase I |
MedlinePlus related topics: Cocaine Abuse
Study Type: Interventional
Study Design: Treatment, Double-Blind, Placebo Control, Crossover Assignment
Official Title: Cocaine-Metyrapone Interaction Study
Expected Total Enrollment: 12
Study start: November 2001; Study completion: May 2002
To evaluate the safety of metyrapone (MRP) for using in an outpatient study in which participants would be given 2 750 mg doses of MRP per week. Secondary study goals are to evaluate the possible efficacy of MRP as a treatment for cocaine dependence and to compare 3 factors hypothesized to induce cocaine craving: cocaine cues, stress, and cocaine itself. This study will utilize a Double Blind, placebo-controlled crossover design with 3 factors: 1) medication 2) relapse trigger and 3) infusion for an 11 day in-patient treatment.
Eligibility
Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Male or Females between 18 and 45 yrs of age; cocaine dependence according to DSM-4; females of child-bearing potential must test non-pregnant and use adequate birth control; be able to provide consent, comply with protocol requirements and try to complete all study treatments.
Exclusion Criteria:
Additional criteria available during screening at the site.
Location Information
Ohio
Cincinnati VA Medical Center, Cincinnati, Ohio, 45220, United States
Theresa Winhusen, Ph.D., Principal Investigator, VA Medical Center-Cincinnati
More Information
Record last reviewed: August 2003
Last Updated: February 16, 2005
Record first received: April 5, 2002
ClinicalTrials.gov Identifier: NCT00033098
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005

Not Signed In -


